VolitionRx reports Q2 earnings beat, misses revenue estimates

VolitionRx Ltd reported second-quarter earnings that exceeded analyst expectations, though revenue lagged behind projections as the diagnostics company navigated a challenging market environment.

The company posted adjusted earnings of 6 cents per share, topping the 0 cent forecast from analysts surveyed by Refinitiv. Revenue, however, totaled $11.2 million, falling short of the $12.5 million estimate and marking a 12% decline from the same period last year.

VolitionRx attributed the revenue shortfall to softer demand across its clinical laboratory and product segments, compounded by ongoing supply chain constraints and pricing pressures. The company maintained its full-year guidance, reaffirming revenue projections of $45 million to $50 million, citing expected stabilization in demand and operational efficiencies.

Chief Executive Officer Cameron Reynolds highlighted progress in expanding the company’s test menu and geographic reach, particularly in Europe and Asia, as key drivers for long-term growth. "While near-term headwinds persist, we remain focused on executing our strategy to drive sustainable revenue growth and margin improvement," Reynolds stated.

Analysts noted that VolitionRx’s earnings beat reflects operational discipline but emphasized that revenue recovery remains critical to restoring investor confidence amid broader sector volatility. Shares of VolitionRx were down 3% in pre-market trading following the report.

The diagnostics sector has faced mixed performance in 2024, with companies balancing cost management against uneven demand recovery post-pandemic. VolitionRx’s results underscore the uneven pace of normalization in the industry.